Castle biosciences stock.
CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 77-0701774 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) ... registrant’s common stock on June 30, 2020, as reported by the Nasdaq Global Market. As of March 5, 2021, there were 24,978,424 shares of …
Get the latest Castle Biosciences, Inc. (CSTL) stock news and headlines to help you in your trading and investing decisions.Innovators With A Proven Track Record of Success. An experienced team with deep expertise in discovering, developing, and commercializing diagnostic and prognostic tests. Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes. The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days.thefly.com — Castle Biosciences raises FY23 revenue view to at least $200M, consensus $187.1M News • Nov 1, 2023 GamesIndustry.biz — Remedy posts flat revenue for Q3 2023
Jul 7, 2023 · In the last 3 months, 12 analysts have offered 12-month price targets for Castle Biosciences. The company has an average price target of $34.83 with a high of $41.00 and a low of $25.00. Below is ... Nov 30, 2023 · A high-level overview of Castle Biosciences, Inc. (CSTL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Castle Biosciences stock gains ~9% after co reports beat-and-raise Q2 SA News Tue, Aug. 09, 2022 1 Comment. Castle Biosciences GAAP EPS of -$0.06 beats by $0.70, revenue of $34.8M beats by $6.43M
White Castle does not allow for the purchase of franchises. Each of the restaurants is privately owned and operated through the White Castle parent company. Because the company is privately owned, it doesn’t offer stock options to the publi...Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma ...In the last 3 months, 12 analysts have offered 12-month price targets for Castle Biosciences. The company has an average price target of $34.83 with a high of $41.00 and a low of $25.00.Castle Biosciences has risen higher in 1 of those 4 years over the subsequent 52-week period, corresponding to a historical accuracy of 25%. Is Castle Biosciences Stock Undervalued? The current Castle Biosciences [ CSTL] share price is $19.99. The Score for CSTL is 73, which is 46% above its historic median score of 50, and infers lower risk ...
3 Haz 2023 ... The company's shares closed yesterday at $22.73. Souda covers the Healthcare sector, focusing on stocks such as Guardant Health, Repligen, and ...
Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx-Melanoma in patients diagnosed with cutaneous melanoma.
Castle Biosciences Inc Credit and Debit Option Spread prices and quotes.Stocks CSTL Overview Castle Biosciences Inc. U.S.: Nasdaq About Castle Biosciences Inc. Average price target from ratings: $ Full Ratings 52.55K (21.02% of Avg) 65 Day …PURPOSE KRAS is the most mutated proto-oncogene that has been identified in cancer, and treatment of patients with KRAS mutations remains an arduous challenge. Recently, KRASG12C mutation has attracted special interest because it is now considered potentially druggable with recently developed covalent small-molecule KRASG12C inhibitors. …Dec 1, 2023 · CSTL Earnings Date and Information. Castle Biosciences last released its earnings results on November 2nd, 2023. The reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.66. The company earned $61.49 million during the quarter, compared to the consensus estimate of $44.94 million. Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently down 22.91% so far this month. During the month of October, Castle Biosciences Inc’s stock price has reached a high of $16.84 and a low of $12.07. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to ...Castle Biosciences reports exceptional Q3 2023 results with a 66% increase in revenue to $61.5 million and a 52% increase in total test reports. They raise their full-year 2023 revenue guidance to at least $200 million from $180 million. ... Net loss for the third quarter, which includes non-cash stock-based compensation expense of $13.0 million, …Europe PMC is an archive of life sciences journal literature.
The primary residents of European castles during the Middle Ages were the lord and lady of the realm. These might be royalty or simply the liege lords of the district where the castle was built.Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma in patients …Mar 1, 2023 · Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.25 per share a year ago. The 31-GEP test (DecisionDx-Melanoma; Castle Biosciences Inc, Friendswood, TX) was used to analyze the expression of 27 prognostic genes (28 probes) and three control genes from primary CM tumors, as previously described. 21 All 31-GEP testing was performed in a College of American Pathologists–accredited and Clinical Laboratory Improvement ...Get the latest Castle Biosciences, Inc. (CSTL) stock news and headlines to help you in your trading and investing decisions.Nov 22, 2023 · November 22, 2023 at 3:28 AM · 2 min read. Last week, Castle Biosciences, Inc. ( NASDAQ:CSTL) insiders, who had purchased shares in the previous 12 months were rewarded handsomely. The shares ... Shares of Castle Biosciences, Inc. have returned +1.9% over the past month versus the Zacks S&P 500 composite's -1.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it ...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire AltheaDx, Inc. (AltheaDx). AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx) testing services that ...DOI: 10.1200/JOP.2017.022152 Journal of Oncology Practice - published online before print March 28, 2017 . PMID: 28350513
Mr. Harrison CSTL stock SEC Form 4 insiders trading. Miles has made over 2 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 3,825 units of CSTL stock worth $76,041 on 2 June 2023.. The largest trade he's ever made was exercising 3,825 units of Castle Biosciences …But note: Castle Biosciences may not be the best stock to buy.So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).. Please note, the ...Apr 5, 2022 · AltheaDx filed for an initial public stock offering in December 2014 but shelved the proposed stock sale in early 2015. Castle Biosciences, which went public in 2019, makes tests that help guide ... Howl’s Moving Castle is a beloved Japanese animated film that has captured the hearts of audiences worldwide since its release in 2004. Based on the novel by Diana Wynne Jones, the film tells the story of a young woman named Sophie who is c...Castle Biosciences stock declined 14% over a five-day trading period ending 3/10/2021, compared to a broader market (S&P500) rise of 2.3%; A change of -14% or more over five trading days is a 4% ...Employment: Castle Biosciences. Stock and Other Ownership Interests: Castle Biosciences. Patents, Royalties, Other Intellectual Property: Chimeric antigen receptors (CARs) and CAR-expressing T cells are provided that can specifically target cells that express an elevated level of a target antigen. Likewise, methods for specifically …Castle Biosciences reports exceptional Q3 2023 results with a 66% increase in revenue to $61.5 million and a 52% increase in total test reports. They raise their full-year 2023 revenue guidance to at least $200 million from $180 million. ... Net loss for the third quarter, which includes non-cash stock-based compensation expense of $13.0 million, …At closing, Castle will pay $30 million in initial consideration to Cernostics security holders, which may consist entirely of cash or $20 million in cash and $10 million in common stock of Castle ...The estimated Net Worth of Mara G. Aspinall is at least $2.79 Million dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over $1,995,313 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.In the last 3 months, 12 analysts have offered 12-month price targets for Castle Biosciences. The company has an average price target of $34.83 with a high of $41.00 and a low of $25.00.
Castle Biosciences announced that it has completed its acquisition of AltheaDx, Inc. ... up to an additional $75.0 million in cash and common stock will be payable in connection with the ...
Castle Biosciences. Sales (Current Employee) - Friendswood, TX - March 16, 2021. Castle Biosciences is a very culture & mission driven company that genuinely cares for their employees. Working at Castle for almost 5 years now, I can confidently say that I am a valued employee, who is respected as an individual in a company of 240+ employees.
Mr. Spiess CSTL stock SEC Form 4 insiders trading. Bernhard has made over 9 trades of the Castle Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 1,500 units of CSTL stock worth $29,820 on 10 December 2021.. The largest trade he's ever made was selling 40,000 units of Castle …Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2023. “Castle delivered a strong start to the year,” said Derek Maetzold, president and chief executive officer of Castle Biosciences.Castle Biosciences Price Performance. NASDAQ CSTL traded up $0.07 during trading on Monday, reaching $20.04. The company’s stock had a trading volume of 33,667 shares, compared to its average ...Biosciences; Research Funding - Castle Biosciences. CPG: Other Remuneration - Indiana University. DM: President and CEO - Castle Biosciences; Stock Ownership - Castle Biosciences. KMO: Director of ...Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive ...CSTL Earnings Date and Information. Castle Biosciences last released its earnings results on November 2nd, 2023. The reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.66. The company earned $61.49 million during the quarter, compared to the consensus estimate of $44.94 million.Nikkei 225. 33,424.41. -0.28%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Castle Biosciences Inc (CSTL.OQ) real-time stock quotes, news, price and financial information from ...Nov 2, 2023 · Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating the personalized information our tests provide.
The 31-GEP test (DecisionDx-Melanoma; Castle Biosciences Inc, Friendswood, TX) was used to analyze the expression of 27 prognostic genes (28 probes) and three control genes from primary CM tumors, as previously described. 21 All 31-GEP testing was performed in a College of American Pathologists–accredited and Clinical Laboratory Improvement …Castle Biosciences has risen higher in 1 of those 4 years over the subsequent 52-week period, corresponding to a historical accuracy of 25%. Is Castle Biosciences Stock Undervalued? The current Castle Biosciences [ CSTL] share price is $19.99. The Score for CSTL is 73, which is 46% above its historic median score of 50, and infers lower risk ...Castle Biosciences is registered under the ticker NASDAQ:CSTL . Their stock opened with $16.00 in its Jul 24, 2019 IPO. Castle Biosciences is funded by 11 investors. Spindletop Capital Management and BrightEdge Fund are the most recent investors. Castle Biosciences has acquired 3 organizations. Their most recent acquisition was AltheaDx …Instagram:https://instagram. canadianpacificfastenal coamd stock predictionvalue 1943 penny At Castle Biosciences, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.The Castle Biosciences, Inc. stock price gained 1.95% on the last trading day (Wednesday, 29th Nov 2023), rising from $19.48 to $19.86. During the last trading day the stock fluctuated 3.77% from a day low at $19.61 to a day high of $20.35. The price has risen in 7 of the last 10 days and is up by 3.76% over the past 2 weeks. canoo stocksweat In a report released on July 7, Puneet Souda from SVB Securities maintained a Buy rating on Castle Biosciences (CSTL – Research Report).The company’s shares closed last Friday at $20.30 ... stock broking companies in india White Castle restaurants have operated in the United States for almost 100 years. That’s amazing enough, but the biggest shocker is that the more than 375 fast food restaurants are still completely under the company’s control. That feat is ...Castle Biosciences Inc Credit and Debit Option Spread prices and quotes.